Amgen Inc. (AMGN): Price and Financial Metrics
Amgen Inc. (AMGN)
Today's Latest Price: $223.46 USD
Updated Oct 27 6:55pm
Add AMGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
AMGN Stock Summary
- With a market capitalization of $131,716,673,060, Amgen Inc has a greater market value than 98.54% of US stocks.
- AMGN's went public 34.84 years ago, making it older than 92.89% of listed US stocks we're tracking.
- The volatility of Amgen Inc's share price is greater than that of merely 2.64% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Amgen Inc are TXN, AZN, LLY, BMY, and SAP.
- AMGN's SEC filings can be seen here. And to visit Amgen Inc's official web site, go to www.amgen.com.
AMGN Stock Price Chart Interactive Chart >
AMGN Price/Volume Stats
| Current price | $223.46 | 52-week high | $264.97 |
| Prev. close | $224.89 | 52-week low | $177.05 |
| Day low | $223.14 | Volume | 1,934,300 |
| Day high | $225.95 | Avg. volume | 2,865,344 |
| 50-day MA | $243.17 | Dividend yield | 2.86% |
| 200-day MA | $231.94 | Market Cap | 130.88B |
Amgen Inc. (AMGN) Company Bio
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company was founded in 1980 and is based in Thousand Oaks, California.
AMGN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $223.46 | $193.25 | -14% |
Below please find a table outlining a discounted cash flow forecast for AMGN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Amgen Inc ranked in the 43th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 13.67%. As for the metrics that stood out in our discounted cash flow analysis of Amgen Inc, consider:
- As a business, AMGN is generating more cash flow than 95% of positive cash flow stocks in the Healthcare.
- Amgen Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than just 18.87% of tickers in our DCF set.
- AMGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than just 18.87% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -16% |
| 1% | -15% |
| 2% | -14% |
| 3% | -13% |
| 4% | -12% |
| 5% | -12% |
Want more companies with a valuation profile/forecast similar to that of Amgen Inc? See IART, DXCM, FONR, PRAH, and RSCF.
Loading social stream, please wait...